JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive for the understanding of myeloproliferative neoplasms (MPN). Activated JAK2 signaling by <i>JAK2</i>, <i>CALR,</i> and <i>MPL</i> mutations has become a focus for the develop...
Saved in:
Main Authors: | Michael Stephan Bader (Author), Sara Christina Meyer (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
JAK2-positive Philadelphia-negative myeloproliferative neoplasms
by: Anjali Sharma, et al.
Published: (2011) -
Mouse models of myeloproliferative neoplasms: JAK of all grades
by: Juan Li, et al.
Published: (2011) -
Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
by: Vladan P. Čokić, et al.
Published: (2015) -
Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: B Bahar, et al.
Published: (2009) -
Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: H Ghafari, et al.
Published: (2009)